Viral Immunology · 2015 · 26 citations · 28 references
Life SciencesImmunologyInfectious DiseasesClinical ImmunologyImmunoregulationMolecular ImmunologyCell-mediated ImmunityRegulatory T CellsT Cell ActivationT Cell BiologyViral HepatitisAntiviral T Cell ResponsesCd4 Positive T CellsProgrammed Cell Death Ligand 1 RegulationProgrammed Cell Death Ligand 1 SignalingProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 SignalingProgrammed Death-ligand 1 Upregulation
Regulatory T cells (Tregs) play a pivotal role in suppressing specific antiviral immune responses during the progression of chronic hepatitis B virus infection (CHB) as well as tumorigenesis. Programmed death-1 ligand-1 (PD-L1) expressed on Tregs can transduce an inhibitory signal into effector T cells through interacting with programmed death-1 (PD-1). However, in CHB patients, the clinical significance of PD-L1 expression on Tregs has not been clearly described. This study investigated the frequency of circulating Tregs and PD-L1 expression on Tregs and analyzed their correlations with clinical parameters. The data show that both the frequency of CD4+CD25+FoxP3+ Tregs and PD-L1 expression on Tregs in the peripheral blood increased significantly in CHB patients when compared with healthy controls. At the same time, it is shown that PD-L1 expression on Tregs was positively correlated with the percentage of Tregs in CHB patients. Moreover, the results demonstrated that both Treg frequency and PD-L1 expression on Tregs positively correlated with the levels of alanine aminotransaminase (ALT) and aspartate aminotransferase (AST), both of which are indicators of the extent of liver injury. Taken together, these findings suggest that PD-L1 on Tregs might contribute to progression of hepatitis B virus infection through mediating the inhibitory function of Tregs. Thereby, blockade of interaction between Treg-expressing PD-L1 and PD-1 on effector T cells may be adopted as a potential therapeutic approach in CHB.
28
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text
Life Sciences, Immunology, Pathology +14
Restoring function in exhausted CD8 T cells during chronic viral infection
Daniel L. Barber, E. John Wherry, David Masopust et al. · Nature · 2005 · 4K citations
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles, Joseph P. Eder, Gregg Fine et al. · Nature · 2014 · 2.4K citations
Medicine, Oncology, Pharmacology +12
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu‐Hwa Huang, Chen Zhu, Yasuyuki Kondo et al. · Nature · 2014 · 719 citations